Related Experiment Video
Updated: Mar 12, 2026
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
Published on: June 2, 2023
Gut dysbiosis-mediated platelet activation as MASLD and cardiovascular disease link
Francesco Violi1, Pasquale Pignatelli2, Roberto Carnevale3
1Sapienza University of Rome, Latina, Italy.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by liver disease progression and cardiovascular disease (CVD). The mechanism linking MASLD with CVD is not fully understood. Here, we report experimental and clinical studies suggesting that platelet activation may be implicated in the pathogenesis of MASLD and CVD.
Insights
Platelet activation may link metabolic dysfunction-associated steatotic liver disease (MASLD) to cardiovascular disease (CVD). This study investigates the underlying mechanisms connecting these conditions, highlighting a potential shared pathway.
Area of Science:
- Cardiovascular Medicine
- Hepatology
- Hematology
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern linked to cardiovascular disease (CVD).
- The precise mechanisms connecting MASLD and CVD remain incompletely understood.
- Platelet activation is a known factor in cardiovascular events.
Purpose of the Study:
- To investigate the potential role of platelet activation in the pathogenesis of MASLD.
- To explore the link between platelet activation and the progression of cardiovascular disease in patients with MASLD.
- To elucidate the mechanistic connection between MASLD and CVD.
Main Methods:
- Experimental studies involving relevant models.
- Clinical data analysis from patient cohorts.
- Assessment of platelet activation markers and liver/cardiovascular health indicators.
Main Results:
- Evidence suggests a significant association between platelet activation and MASLD.
- Platelet activation markers correlate with the severity of liver steatosis and cardiovascular risk.
- Experimental findings support a mechanistic link involving platelets.
Conclusions:
- Platelet activation emerges as a potential key mediator in the progression of MASLD and its association with CVD.
- Targeting platelet activation may offer a novel therapeutic strategy for patients with MASLD and comorbid CVD.
- Further research is warranted to fully elucidate the role of platelets in MASLD-associated cardiovascular complications.
More Related Videos
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:26Coronary Artery Disease II: Pathophysiology
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:30Atherosclerosis I: Introduction
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...